Verastem Inc Earnings Call Highlights Growth And Risk

Verastem Inc ((VSTM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Verastem Inc’s latest earnings call struck a cautiously optimistic tone as management balanced solid commercial traction with ongoing financial strain. Executives highlighted steady uptake of the company’s LGSOC franchise and promising data from its VS-7375 program, while acknowledging that high cash burn, immature launch metrics and operational hurdles keep execution risk firmly on investors’ radar.

Commercial Launch Momentum and Revenue

Verastem reported Q1 2026 net product revenue of $18.7 million, bringing cumulative sales since the May 2025 launch to nearly $50 million. Management emphasized consistent quarter‑over‑quarter growth and said they expect an increase from Q1 to Q2 as prescriber activity and patient starts continue to build.

LGSOC Franchise Nearing Self-Sustainability

The company reiterated that its LGSOC franchise, marketed as the AVMAPKI FAKZYNJA CO‑PACK, should become self‑sustaining in the second half of 2026. By that point, management expects CO‑PACK revenues to fully fund both commercial operations and ongoing trials of the avutometinib plus defactinib combination.

Patient Access and Affordability Metrics

Access programs remain central to adoption, with about 65% of commercially eligible patients using the Verastem Cares Co‑Pay Program. For those patients, average out‑of‑pocket cost sits under $30, while time to fill initial prescriptions holds at 12 to 14 days and payer mix is roughly evenly split between commercial plans and Medicare.

Robust VS-7375 (Target-D) Clinical Program Advancement

The VS‑7375 Target‑D program advanced on several fronts, with the Target‑D‑101 Phase I/II trial continuing dose escalation up to 1,200 milligrams. In parallel, Verastem has launched three Phase II registration‑directed studies in pancreatic, non‑small cell lung and colorectal cancers, using a 900 milligram dose and focusing on overall response rate and duration of response.

PK and Tolerability Support Higher Go-Forward Dose

Updated pharmacokinetic data indicate that 900 milligrams of VS‑7375 achieves serum levels at or above target with a clear separation from 600 milligrams. Importantly, U.S. tolerability has looked favorable so far, with no significant liver or hematologic toxicities observed and responses already seen at the lower 600 milligram dose.

Operational Leadership and Commercial Optimization

To sharpen execution, Verastem appointed a seasoned Chief Commercial Officer and added sales headcount, including two new field roles. The company also launched a “Reimagine Recurrent LGSOC” campaign and expanded post‑prescription outreach, aiming to drive earlier use at first recurrence and improve on‑therapy adherence.

Balance Sheet and Runway

Verastem ended the quarter with $181.7 million in cash, cash equivalents and investments, a level management believes funds operations into the first half of 2027. The company is actively pursuing nondilutive financing options as it leans on future CO‑PACK revenues to extend runway and support both commercial and R&D activities.

Seasonal and Access Headwinds Impacting Q1

First‑quarter performance was tempered by familiar seasonal factors, including insurance churn, reverifications and severe weather that disrupted treatment patterns. These issues delayed some refills, forced temporary reliance on free drug programs and ultimately weighed on short‑term new patient starts and revenue timing.

Early Discontinuations Among Some Early Adopter Patients

Management noted that certain early adopter physicians treated patients who were already late in their disease course, including individuals near hospice. These patients tended to discontinue therapy earlier than expected, muting near‑term treatment duration and refill volumes despite the growing base of active prescribers.

High R&D and SG&A Relative to Revenue

The company’s cost structure remains heavy, with Q1 R&D expense of $38.2 million and SG&A of $22.3 million against $18.7 million in product revenue. That translates to R&D at over twice quarterly revenue and SG&A exceeding it as Verastem funds multiple trials and builds out its commercial infrastructure.

Ongoing Net Loss and Cash Burn

Non‑GAAP adjusted net loss for the quarter came in at $42.7 million, nearly flat year on year in dollar terms but improved on a per‑share basis due to share count changes. With runway into early 2027 and losses still sizable, the company underscored the need to secure additional, ideally nondilutive, capital within roughly the next year.

Uncertain Early Commercial Metrics (Duration / Refills)

Despite growing prescriber numbers and patient enrollments, Verastem said it is too early to provide reliable figures for average duration of therapy or refills. The immaturity of these data points makes near‑term revenue forecasting less precise, leaving investors dependent on directional trends rather than hardened metrics.

Operational Complexity Around Optimal Dosing and Formulation

VS‑7375 development faces practical dosing constraints because the current capsule strength is 100 milligrams, making 900 milligrams near the upper limit of convenient single dosing. Reaching 1,200 milligrams requires split dosing, and while larger pill formulations are in development, they could influence timing and assessment of higher‑dose regimens.

Guidance and Forward-Looking Outlook

Management reaffirmed expectations that SG&A will remain roughly flat through 2026, with incremental commercial and A+ R&D spend each running about $10 million to $15 million per quarter. On the pipeline side, first patients in the Target‑D Phase II trials are expected mid‑year, additional safety and PK updates are slated for the first half, and the company is targeting response and durability benchmarks consistent with accelerated approval pathways.

Verastem’s earnings call painted the picture of a company in transition, with a young but growing commercial franchise and a high‑potential oncology pipeline offset by sizeable losses and execution risks. Investors will be watching closely to see whether rising CO‑PACK revenues and VS‑7375 progress can outpace cash burn and operational complexity over the next 12 to 18 months.